Icatibant

What is Icatibant?

Icatibant is a synthetic decapeptide that functions as a selective and competitive antagonist of the bradykinin B2 receptor. Marketed under the brand name Firazyr, it was developed by Jerini AG (later acquired by Shire, now part of Takeda) specifically for the treatment of acute attacks of hereditary angioedema (HAE). The compound is a peptidomimetic, meaning it mimics the structure of natural bradykinin but blocks its receptor rather than activating it, effectively interrupting the inflammatory cascade responsible for HAE symptoms.

Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of severe swelling in the skin, gastrointestinal tract, and airways. These attacks are mediated by excessive bradykinin activity resulting from a deficiency or dysfunction of C1-esterase inhibitor. By directly blocking the bradykinin B2 receptor, icatibant addresses the downstream mediator of swelling rather than the upstream enzyme deficiency, providing rapid symptomatic relief during acute episodes.

Icatibant received FDA approval in 2011 for the treatment of acute HAE attacks in adults 18 years and older. It has also been approved by the European Medicines Agency (EMA) since 2008. The compound is classified as a prescription medication and is available exclusively as a pre-filled syringe for subcutaneous self-administration, making it suitable for on-demand use by patients experiencing an HAE attack.

Clinical Research & Evidence

The clinical development of icatibant was supported by the FAST (For Angioedema Subcutaneous Treatment) clinical trial program, which included three pivotal Phase III studies. The FAST-1 trial, conducted primarily in the United States, and the FAST-2 trial, conducted in Europe, both demonstrated that icatibant provided statistically significant improvement in symptom severity compared to placebo and tranexamic acid, respectively. Patients treated with icatibant experienced a median time to onset of symptom relief of approximately 2 hours.

The FAST-3 trial, a randomized, double-blind, placebo-controlled study, further confirmed these findings. Research indicated that icatibant-treated patients achieved clinically meaningful symptom relief significantly faster than those receiving placebo, with a median time to 50% reduction in symptom severity of approximately 2 hours versus 19.8 hours for placebo. The study also demonstrated that icatibant was effective across different attack locations, including cutaneous, abdominal, and laryngeal attacks.

Long-term open-label extension studies have suggested that icatibant maintains its efficacy over repeated use, with no evidence of tachyphylaxis (diminishing response) developing over time. Research also indicates that the compound may have potential applications beyond HAE, with preliminary investigations exploring its role in ACE inhibitor-induced angioedema, though this remains an off-label use and further studies are needed to establish efficacy in this population.

Post-marketing surveillance and real-world data have supported the safety and efficacy profile established in clinical trials. Studies suggest that self-administration by trained patients is both feasible and effective, with patients reporting high satisfaction rates with the pre-filled syringe delivery system. The ability to self-treat at home has been associated with earlier treatment initiation and potentially shorter attack duration.

Potential Benefits

• Rapid symptom relief: Clinical studies indicate that icatibant may provide onset of symptom relief within approximately 2 hours of administration, addressing acute HAE swelling episodes promptly.
• Targeted mechanism of action: As a selective bradykinin B2 receptor antagonist, icatibant directly blocks the mediator responsible for HAE-related swelling without broadly suppressing the immune system.
• Self-administration capability: The pre-filled syringe design allows trained patients to self-inject during an attack, eliminating the need for emergency department visits for many episodes.
• Consistent efficacy over repeated use: Long-term data suggest that icatibant maintains its effectiveness across multiple HAE attacks without evidence of diminished response.
• Favorable safety profile: Clinical trials and post-marketing data indicate that icatibant is generally well-tolerated, with injection site reactions being the most commonly reported adverse effect.
• Effective across attack types: Research suggests efficacy for cutaneous (skin), abdominal, and laryngeal (throat) HAE attacks, covering the major presentation types.
• No requirement for IV access: Unlike some other HAE treatments that require intravenous infusion, icatibant is administered subcutaneously, simplifying the treatment process.
• Room temperature storage: The pre-filled syringe can be stored at room temperature, making it convenient for patients to carry and use as needed.

Dosing Protocol

The standard FDA-approved dose is 30 mg administered as a single subcutaneous injection in the abdominal area. If symptoms persist or recur, additional doses of 30 mg may be administered at intervals of at least 6 hours, with a maximum of three injections (90 mg) within a 24-hour period. No dose titration is required. Patients should always follow their prescribing provider's specific guidance regarding dosing and administration timing.

Reconstitution Guide

Icatibant (Firazyr) is supplied as a ready-to-use, pre-filled syringe containing 30 mg of icatibant in 3 mL of solution (10 mg/mL concentration). No reconstitution or dilution is required. The pre-filled syringe comes with a 25-gauge needle already attached and is ready for immediate subcutaneous administration.

Before use, visually inspect the solution. It should be clear and colorless. Do not use if the solution appears cloudy, contains particles, or if the syringe is damaged. Allow the syringe to reach room temperature for a few minutes before injection if it has been stored in a cooler environment.

Half-Life & Pharmacokinetics

Icatibant has a relatively short elimination half-life of approximately 1 to 2 hours following subcutaneous administration. After injection, the compound is rapidly absorbed, reaching peak plasma concentrations (Cmax) within approximately 30 minutes. The absolute bioavailability of subcutaneous icatibant is approximately 97%, indicating near-complete absorption from the injection site into systemic circulation.

The compound is metabolized primarily through proteolytic cleavage, producing inactive metabolites that are subsequently eliminated by the kidneys. Approximately 90% of the administered dose is excreted in the urine as metabolites. Icatibant exhibits a volume of distribution of approximately 29 liters, suggesting moderate tissue distribution. The rapid onset and relatively short duration of action are consistent with its role as an acute on-demand treatment, with pharmacological effects typically becoming apparent within 30 to 60 minutes of injection and the compound being largely cleared from the body within 6 to 8 hours.

Administration & Injection Sites

Icatibant is administered via subcutaneous injection using the pre-filled syringe provided. The recommended injection site is the abdominal area, approximately 2 to 4 inches below the navel and away from any scars or areas of tenderness. Patients should avoid injecting into the same exact spot repeatedly to reduce the risk of injection site reactions.

Before injecting, clean the injection site with an alcohol swab and allow it to dry. Pinch a fold of skin at the injection site and insert the needle at a 45 to 90 degree angle. Slowly inject the full contents of the syringe over approximately 30 seconds. After injection, apply gentle pressure with a gauze pad but do not rub the area. Dispose of the used syringe in an appropriate sharps container.

• Primary site: Abdomen (preferred, 2-4 inches below navel)
• Alternative site: Thigh (outer, upper area)
• Alternative site: Upper arm (posterior area, if assisted by caregiver)

Patients and caregivers should receive proper training from a healthcare provider before attempting self-administration. The injection technique should be reviewed periodically to ensure correct practice is maintained.

Side Effects & Safety

Icatibant is generally well-tolerated based on clinical trial data and post-marketing experience. The most commonly reported adverse effects are related to the injection site.

Common Side Effects

• Injection site reactions (very common, >90%): Redness, swelling, warmth, itching, or pain at the injection site. These reactions are typically mild to moderate and resolve within a few hours.
• Pyrexia (common): Low-grade fever may occur following injection.
• Transaminase elevation (common): Mild, temporary increases in liver enzymes have been reported.

Uncommon Side Effects

• Dizziness (uncommon): Occasional lightheadedness or dizziness following administration.
• Nausea (uncommon): Mild gastrointestinal discomfort has been reported in some patients.
• Rash (uncommon): Skin rash unrelated to the injection site has been reported rarely.

Rare Side Effects

• Hypersensitivity reactions (rare): Although rare, allergic reactions to icatibant or its excipients may occur.

Stacking & Interactions

Icatibant is typically used as a standalone acute treatment for HAE attacks. However, patients with HAE may also use prophylactic therapies concurrently. Understanding potential interactions is important for safe use.

No formal drug interaction studies have identified clinically significant pharmacokinetic interactions. However, because icatibant blocks bradykinin B2 receptors, it may theoretically interfere with the blood pressure-lowering effects of ACE inhibitors, which work in part through bradykinin-mediated mechanisms. Patients taking ACE inhibitors should discuss this with their healthcare provider.

Storage & Handling

Icatibant pre-filled syringes should be stored at room temperature between 2 and 25 degrees Celsius (36 to 77 degrees Fahrenheit). The product does not require refrigeration for routine storage, which is a practical advantage for patients who need to carry it at all times for emergency use. Do not freeze the pre-filled syringes.

Store the syringes in the original carton to protect from light. The shelf life of icatibant when stored according to label conditions is typically 3 years from the date of manufacture. Check the expiration date on the packaging before each use and replace expired syringes promptly.

For travel, icatibant can be transported at ambient temperatures without requiring a cold chain, though extreme heat (above 25 degrees Celsius) should be avoided. Consider using an insulated pouch during hot weather. Keep a carry letter from your prescriber when traveling, especially internationally, to explain the medical necessity of carrying injectable medication.

Signs of degradation: Discard the syringe if the solution appears cloudy, discolored, or contains visible particles. Do not use if the syringe barrel is cracked or the needle cap is missing.

Legal & Regulatory Status

Icatibant (Firazyr) is an FDA-approved prescription medication in the United States, approved in August 2011 for the treatment of acute attacks of hereditary angioedema in adults 18 years of age and older. It is classified as a prescription-only medication and cannot be obtained over the counter.

In Europe, icatibant received marketing authorization from the European Medicines Agency (EMA) in July 2008, with broader approval including adolescent patients (aged 2 years and above in some jurisdictions). The compound is also approved in numerous other countries including Canada, Australia, and several Asian and South American nations. Generic versions of icatibant have become available in some markets following patent expiration, potentially improving access and affordability.

Icatibant is not a controlled substance and does not carry the scheduling restrictions associated with opioids or other controlled medications. However, it remains a prescription-only product in all approved markets and requires a valid prescription from a licensed healthcare provider.

Recommended Bloodwork & Monitoring

While icatibant is used on an as-needed basis for acute HAE attacks and does not require routine pre-treatment laboratory monitoring for each administration, patients with HAE should maintain regular follow-up with their healthcare provider for overall disease management.

Baseline Assessments (HAE Diagnosis)

• C4 complement level: Typically low in HAE patients, used as a screening test
• C1-esterase inhibitor (C1-INH) level and function: Quantitative and functional assays to confirm HAE type
• C1q level: To distinguish hereditary from acquired angioedema
• Complete blood count (CBC): Baseline hematologic assessment
• Liver function tests (LFTs): Baseline assessment, as mild transaminase elevations have been reported

Ongoing Monitoring

• Attack frequency tracking: Document attack frequency, severity, and response to treatment
• Liver function tests: Periodic assessment recommended, especially with frequent use
• Quality of life assessments: Regular evaluation of disease impact on daily functioning

Frequently Asked Questions

Related Compounds